Citations (65)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Maede Khalifeloo, Soofia Naghdi, Noureddin Nakhostin Ansari, Jan Dommerholt & Mohammad Ali Sahraian. (2022) Dry needling for the treatment of muscle spasticity in a patient with multiple sclerosis: a case report. Physiotherapy Theory and Practice 38:13, pages 3248-3254.
Read now
Read now
Articles from other publishers (64)
Fiona Doherty, Paul Powell, Ciara McBride & Kenneth Monaghan. (2023) Physical telerehabilitation interventions for gait and balance in multiple sclerosis: A scoping review. Journal of the Neurological Sciences, pages 122827.
Crossref
Crossref
Ferda Selcuk Muhtaroglu, Beliz Belgen Kaygisiz, Sila Usar Incirli & Turhan Kahraman. (2023) Dalfampridine as a promising agent in the management of hereditary spastic paraplegia: A triple-blinded, randomized, placebo-controlled pilot trial. Journal of Clinical Neuroscience 117, pages 136-142.
Crossref
Crossref
Biswamohan Mishra, Pachipala Sudheer, Ayush Agarwal, M. Vasantha Padma Srivastava, Nilima & Venugopalan Y. Vishnu. (2023) Minimal Clinically Important Difference (MCID) in Patient-Reported Outcome Measures for Neurological Conditions. Annals of Indian Academy of Neurology Publish Ahead of Print.
Crossref
Crossref
Soofia Naghdi, Noureddin Nakhostin Ansari, Afarin Haghparast, Amin Nakhostin-Ansari, Maede Khalifeloo, Mahmoud Biglar, Roghie Lotfi & Scott Hasson. (2023) Responsiveness of Persian 12-Item multiple sclerosis walking scale: a replication study. BMC Research Notes 16:1.
Crossref
Crossref
Aylin Bilgin, Gülsah Kesik & Leyla Ozdemir. (2022) The Effects of Cooling Therapies on Fatigue, Physical Activity, and Quality of Life in Multiple Sclerosis. Rehabilitation Nursing 47:6, pages 228-236.
Crossref
Crossref
Renan L. Monteiro, Jane S. S. P. Ferreira, Érica Q. Silva, Ronaldo H. Cruvinel-Júnior, Jady L. Veríssimo, Sicco A. Bus & Isabel C. N. Sacco. (2022) Foot–ankle therapeutic exercise program can improve gait speed in people with diabetic neuropathy: a randomized controlled trial. Scientific Reports 12:1.
Crossref
Crossref
Jeffrey A Cohen, Michelle H Cameron, Myla D Goldman, Andrew D Goodman, Aaron E Miller, Anne Rollins, Lily Llorens, Rajiv Patni, Robert Elfont & Reed Johnson. (2021) A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment. Multiple Sclerosis Journal 28:5, pages 817-830.
Crossref
Crossref
Gabriel Pardo, Samantha Coates & Darin T. Okuda. (2021) Outcome measures assisting treatment optimization in multiple sclerosis. Journal of Neurology 269:3, pages 1282-1297.
Crossref
Crossref
Bobbette J Miller, Thubi HA Kolobe, Rebecca D Larson, Brian A Pribble, Gabriel Pardo & Shirley A James. (2022) Functional intermuscular reduction in spasticity for people with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical 8:1, pages 205521732110615.
Crossref
Crossref
L Carolina Carrere, Melisa Taborda, Carlos Ballario & Carolina Tabernig. (2021) Effects of brain-computer interface with functional electrical stimulation for gait rehabilitation in multiple sclerosis patients: preliminary findings in gait speed and event-related desynchronization onset latency. Journal of Neural Engineering 18:6, pages 066023.
Crossref
Crossref
Nik Krajnc, Thomas Berger & Gabriel Bsteh. (2021) Measuring Treatment Response in Progressive Multiple Sclerosis—Considerations for Adapting to an Era of Multiple Treatment Options. Biomolecules 11:9, pages 1342.
Crossref
Crossref
Anıl Tekeoglu Tosun, Yeldan Ipek, Arzu Razak Ozdincler & Sabahattin Saip. (2020) The efficiency of mirror therapy on drop foot in Multiple Sclerosis Patients. Acta Neurologica Scandinavica 143:5, pages 545-553.
Crossref
Crossref
Carol Sames & Amy DeBlois. (2021) Pilot Study to Investigate the Effect of a 10-Week Aquatic Exercise Program on Individuals With High Levels of Disability Due to Multiple Sclerosis. Journal of Aquatic Physical Therapy 29:1, pages 2-13.
Crossref
Crossref
Katrina Louise Williams, Nancy Louise Low Choy & Sandra Gail Brauer. (2020) Center‐Based Group and Home‐Based Individual Exercise Programs Have Similar Impacts on Gait and Balance in People With Multiple Sclerosis: A Randomized Trial. PM&R 13:1, pages 9-18.
Crossref
Crossref
Laura De Giglio, Francesca Cortese & Elena Maria Pennisi. (2020) Aminopiridines in the treatment of multiple sclerosis and other neurological disorders. Neurodegenerative Disease Management 10:6, pages 409-423.
Crossref
Crossref
Shane Chanpimol, Kimberly Benson, Heidi Maloni, Susan Conroy & Mitchell Wallin. (2020) Acceptability and outcomes of an individualized exergaming telePT program for veterans with multiple sclerosis: a pilot study. Archives of Physiotherapy 10:1.
Crossref
Crossref
Augustine J. Devasahayam, Arthur R. Chaves, Wendy O. Lasisi, Marie E. Curtis, Katie P. Wadden, Liam P. Kelly, Ryan Pretty, Alice Chen, Elizabeth M. Wallack, Caitlin J. Newell, John B. Williams, Hannah Kenny, Matthew B. Downer, Jason McCarthy, Craig S. Moore & Michelle Ploughman. (2020) Vigorous cool room treadmill training to improve walking ability in people with multiple sclerosis who use ambulatory assistive devices: a feasibility study. BMC Neurology 20:1.
Crossref
Crossref
J. Twose, G. Licitra, H. McConchie, K. H. Lam & J. Killestein. (2020) Early-warning signals for disease activity in patients diagnosed with multiple sclerosis based on keystroke dynamics. Chaos: An Interdisciplinary Journal of Nonlinear Science 30:11, pages 113133.
Crossref
Crossref
Marco Kaufmann, Claude Vaney, Laura Barin, Xinglu Liu & Viktor von Wyl. (2020) Long-term worsening of different body functions in persons with progressive multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical 6:4, pages 205521732096451.
Crossref
Crossref
Eloi Magnin, Yoshimasa Sagawa, Thierry Moulin & Pierre Decavel. (2020) What Are the Minimal Detectable Changes in SDMT and Verbal Fluency Tests for Assessing Changes in Cognitive Performance in Persons with Multiple Sclerosis and Non-Multiple Sclerosis Controls?. European Neurology 83:3, pages 263-270.
Crossref
Crossref
Lara A. Pilutti & Robert W. Motl. (2019) Functional Electrical Stimulation Cycling Exercise for People with Multiple Sclerosis. Current Treatment Options in Neurology 21:11.
Crossref
Crossref
A. Barclay, L. Paul, N. MacFarlane & A.K. McFadyen. (2019) The effect of cycling using active-passive trainers on spasticity, cardiovascular fitness, function and quality of life in people with moderate to severe Multiple Sclerosis (MS); a feasibility study.. Multiple Sclerosis and Related Disorders 34, pages 128-134.
Crossref
Crossref
Robert W. Motl, Deborah Backus, Whitney N. Neal, Gary Cutter, Louise Palmer, Robert McBurney, Hollie Schmidt, Francois Bethoux, Jeffrey Hebert, Alexander Ng, Kevin K. McCully & Prudence Plummer. (2019) Rationale and design of the STEP for MS Trial: Comparative effectiveness of Supervised versus Telerehabilitation Exercise Programs for Multiple Sclerosis. Contemporary Clinical Trials 81, pages 110-122.
Crossref
Crossref
Pierre Decavel, Thierry Moulin & Yoshimasa SagawaJr.Jr.. (2019) Gait tests in multiple sclerosis: Reliability and cut-off values. Gait & Posture 67, pages 37-42.
Crossref
Crossref
Thomas Edwards, Robert W. Motl, Emerson Sebastião & Lara A. Pilutti. (2018) Pilot randomized controlled trial of functional electrical stimulation cycling exercise in people with multiple sclerosis with mobility disability. Multiple Sclerosis and Related Disorders 26, pages 103-111.
Crossref
Crossref
Matthew C Streicher, Jay L Alberts, Matthew H Sutliff & Francois Bethoux. (2018) Effects and feasibility of virtual reality system vs traditional physical therapy training in multiple sclerosis patients. International Journal of Therapy and Rehabilitation 25:10, pages 522-528.
Crossref
Crossref
L. Ramió-Torrentà, J.C. Álvarez-Cermeño, R. Arroyo, B. Casanova-Estruch, O. Fernández, J.A. García-Merino, M.A. Hernández, G. Izquierdo, S. Martínez-Yélamos, J. Meca, E. Moral, J. Olascoaga, J.M. Prieto & A. Saiz. (2018) A guide to treating gait impairment with prolonged-release fampridine (Fampyra ® ) in patients with multiple sclerosis. Neurología (English Edition) 33:5, pages 327-337.
Crossref
Crossref
L. Ramió-Torrentà, J.C. Álvarez-Cermeño, R. Arroyo, B. Casanova-Estruch, O. Fernández, J.A. García-Merino, M.A. Hernández, G. Izquierdo, S. Martínez-Yélamos, J. Meca, E. Moral, J. Olascoaga, J.M. Prieto & A. Saiz. (2018) Guía de tratamiento del deterioro de la marcha con fampridina de liberación prolongada (Fampyra ® ) en pacientes con esclerosis múltiple. Neurología 33:5, pages 327-337.
Crossref
Crossref
Laura Barin, Claude Vaney, Milo Alan Puhan & Viktor von Wyl. (2018) Recommended outcome measures for inpatient rehabilitation of multiple sclerosis are not appropriate for the patients with substantially impaired mobility. Multiple Sclerosis and Related Disorders 22, pages 108-114.
Crossref
Crossref
Georgia Andreopoulou, Thomas H. Mercer & Marietta L. van der Linden. (2018) Walking measures to evaluate assistive technology for foot drop in multiple sclerosis: A systematic review of psychometric properties. Gait & Posture 61, pages 55-66.
Crossref
Crossref
Núria Sola-Valls, Yolanda Blanco, María Sepúlveda, Sara Llufriu, Elena H. Martínez-Lapiscina, Irati Zubizarreta, Irene Pulido-Valdeolivas, Carmen Montejo, Pablo Villoslada & Albert Saiz. (2018) Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine. Therapeutic Advances in Neurological Disorders 11, pages 175628641878000.
Crossref
Crossref
Anuschka Grobelny, Janina R. Behrens, Sebastian Mertens, Karen Otte, Sebastian Mansow-Model, Theresa Krüger, Elona Gusho, Judith Bellmann-Strobl, Friedemann Paul, Alexander U. Brandt & Tanja Schmitz-Hübsch. (2017) Maximum walking speed in multiple sclerosis assessed with visual perceptive computing. PLOS ONE 12:12, pages e0189281.
Crossref
Crossref
Esther S. Kim. (2017) Fampridine Prolonged Release: A Review in Multiple Sclerosis Patients with Walking Disability. Drugs 77:14, pages 1593-1602.
Crossref
Crossref
Robert W Motl, Jeffrey A Cohen, Ralph Benedict, Glenn Phillips, Nicholas LaRocca, Lynn D Hudson & Richard Rudick. (2017) Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis. Multiple Sclerosis Journal 23:5, pages 704-710.
Crossref
Crossref
Magaly Lecat, Pierre Decavel, Eloi Magnin, Brigitte Lucas, Vincent Gremeaux & Yoshimasa Sagawa. (2017) Multiple Sclerosis and Clinical Gait Analysis before and after Fampridine: A Systematic Review. European Neurology 78:5-6, pages 272-286.
Crossref
Crossref
Kalman Bencsath, Adham Jammoul, Ali Aminian, Hideharu Shimizu, Carolyn J. Fisher, Philip R. Schauer, Alexander Rae-Grant & Stacy A. Brethauer. (2017) Outcomes of Bariatric Surgery in Morbidly Obese Patients with Multiple Sclerosis. Journal of Obesity 2017, pages 1-5.
Crossref
Crossref
Sarah Morrow. 2017. Case Studies in Multiple Sclerosis. Case Studies in Multiple Sclerosis
77
83
.
Yoshimasa SagawaJr.Jr., Eloi Magnin, Laura Paillot, Thierry Moulin & Pierre Decavel. (2016) Fampridine and quality of life in individuals with multiple sclerosis. SpringerPlus 5:1.
Crossref
Crossref
Katrina L. Williams, Nancy L. Low Choy & Sandra G. Brauer. (2016) Are Changes in Gait and Balance Across the Disease Step Rating Scale in Multiple Sclerosis Statistically Significant and Clinically Meaningful?. Archives of Physical Medicine and Rehabilitation 97:9, pages 1502-1508.
Crossref
Crossref
H.B. Jensen, Sepehr Mamoei, M. Ravnborg, U. Dalgas & E. Stenager. (2016) Distribution-based estimates of minimum clinically important difference in cognition, arm function and lower body function after slow release-fampridine treatment of patients with multiple sclerosis. Multiple Sclerosis and Related Disorders 7, pages 58-60.
Crossref
Crossref
Evan Campbell, Elaine H. Coulter, Paul G. Mattison, Linda Miller, Angus McFadyen & Lorna Paul. (2016) Physiotherapy Rehabilitation for People With Progressive Multiple Sclerosis: A Systematic Review. Archives of Physical Medicine and Rehabilitation 97:1, pages 141-151.e3.
Crossref
Crossref
Etienne Allart, Anne Benoit, Anne Blanchard-Dauphin, Vincent Tiffreau, André Thevenon, Hélène Zephir, Olivier Outteryck, Arnaud Lacour & Patrick Vermersch. (2015) Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life. Journal of Neurology 262:8, pages 1936-1945.
Crossref
Crossref
Robert W. Motl, Norman Putzki, Lara A. Pilutti & Diego Cadavid. (2015) Longitudinal Changes in Self-Reported Walking Ability in Multiple Sclerosis. PLOS ONE 10:5, pages e0125002.
Crossref
Crossref
J. P. Stellmann, A. Neuhaus, N. Götze, S. Briken, C. Lederer, M. Schimpl, C. Heesen & M. Daumer. (2015) Ecological Validity of Walking Capacity Tests in Multiple Sclerosis. PLOS ONE 10:4, pages e0123822.
Crossref
Crossref
Deborah M Miller, Nicolas R Thompson, Jeffrey A Cohen, Robert J Fox, Jen Hartman, Kathleen Schwetz, Devon S Conway & Richard A Rudick. (2014) Factors associated with clinically significant increased walking time in multiple sclerosis: Results of a survival analysis of short-term follow-up data from a clinical database. Multiple Sclerosis Journal 21:4, pages 457-465.
Crossref
Crossref
Lori Mayer, Tina Warring, Stephanie Agrella, Helen L. Rogers & Edward J. Fox. (2015) Effects of Functional Electrical Stimulation on Gait Function and Quality of Life for People with Multiple Sclerosis Taking Dalfampridine. International Journal of MS Care 17:1, pages 35-41.
Crossref
Crossref
Eloi Magnin, Yoshimasa Sagawa Jr, Ludivine Chamard, Eric Berger, Thierry Moulin & Pierre Decavel. (2015) Verbal Fluencies and Fampridine Treatment in Multiple Sclerosis. European Neurology 74:5-6, pages 243-250.
Crossref
Crossref
HB Jensen, M Ravnborg, S Mamoei, U Dalgas & E Stenager. (2014) Changes in cognition, arm function and lower body function after Slow-Release Fampridine treatment. Multiple Sclerosis Journal 20:14, pages 1872-1880.
Crossref
Crossref
J.P. Stellmann, E. Vettorazzi, J. Poettgen & C. Heesen. (2014) A 3meter Timed Tandem Walk is an early marker of motor and cerebellar impairment in fully ambulatory MS patients. Journal of the Neurological Sciences 346:1-2, pages 99-106.
Crossref
Crossref
Abbey Downing, David Van Ryn, Anne Fecko, Christopher Aiken, Sean McGowan, Sarah Sawers, Thomas McInerny, Katie Moore, Louis Passariello & Helen Rogers. (2014) Effect of a 2-Week Trial of Functional Electrical Stimulation on Gait Function and Quality of Life in People with Multiple Sclerosis. International Journal of MS Care 16:3, pages 146-152.
Crossref
Crossref
Andrew D. Goodman, Theodore R. Brown, Randall T. Schapiro, Michael Klingler, Ron Cohen & Andrew R. Blight. (2014) A Pooled Analysis of Two Phase 3 Clinical Trials of Dalfampridine in Patients with Multiple Sclerosis. International Journal of MS Care 16:3, pages 153-160.
Crossref
Crossref
Ilse Baert, Jennifer Freeman, Tori Smedal, Ulrik Dalgas, Anders Romberg, Alon Kalron, Helen Conyers, Iratxe Elorriaga, Benoit Gebara, Johanna Gumse, Adnan Heric, Ellen Jensen, Kari Jones, Kathy Knuts, Benoît Maertens de Noordhout, Andrej Martic, Britt Normann, Bert O Eijnde, Kamila Rasova, Carmen Santoyo Medina, Veronik Truyens, Inez Wens & Peter Feys. (2014) Responsiveness and Clinically Meaningful Improvement, According to Disability Level, of Five Walking Measures After Rehabilitation in Multiple Sclerosis. Neurorehabilitation and Neural Repair 28:7, pages 621-631.
Crossref
Crossref
Richard W. Bohannon & Susan S. Glenney. (2014) Minimal clinically important difference for change in comfortable gait speed of adults with pathology: a systematic review. Journal of Evaluation in Clinical Practice 20:4, pages 295-300.
Crossref
Crossref
Alar Kuusik, Katrin Gross-Paju, Heigo Maamagi & Enar Reilent. (2014) Comparative Study of Four Instrumented Mobility Analysis Tests on Neurological Disease Patients. Comparative Study of Four Instrumented Mobility Analysis Tests on Neurological Disease Patients.
Henrik Boye Jensen, Mads Ravnborg, Ulrik Dalgas & Egon Stenager. (2013) 4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review. Therapeutic Advances in Neurological Disorders 7:2, pages 97-113.
Crossref
Crossref
Peter Feys, Bo Bibby, Anders Romberg, Carme Santoyo, Benoit Gebara, Benoit Maertens de Noordhout, Kathy Knuts, Francois Bethoux, Anders Skjerbæk, Ellen Jensen, Ilse Baert, Claude Vaney, Vincent de Groot & Ulrik Dalgas. (2014) Within-day variability on short and long walking tests in persons with multiple sclerosis. Journal of the Neurological Sciences 338:1-2, pages 183-187.
Crossref
Crossref
Brendan L Limone, Matthew F Sidovar & Craig I Coleman. (2013) Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients. Health and Quality of Life Outcomes 11:1.
Crossref
Crossref
Myla D. GoldmanRobert W. MotlJohn ScagnelliJohn H. PulaJacob J. SosnoffDiego Cadavid. (2013) Clinically meaningful performance benchmarks in MS. Neurology 81:21, pages 1856-1863.
Crossref
Crossref
Meheroz H. Rabadi, Kimberly Kreymborg & Andrea S. Vincent. (2013) Sustained-Release Fampridine (4-Aminopyridine) in Multiple Sclerosis: Efficacy and Impact on Motor Function. Drugs in R&D 13:3, pages 175-181.
Crossref
Crossref
Jana Lizrova Preiningerova, Ulf Baumhackl, Tunde Csepany, Adam Czaplinski, Florian Deisenhammer, Tobias Derfuss, Tanja H. Fabjan, Franz Fazekas, Siegrid Fuchs, Eva Havrdova, Alenka Horvath Ledinek, Zsolt Illes, Sasa Sega Jazbec, Eleonora Klimova, Samuel Komoly, Egon Kurca, Michael Linnebank, Lubomir Lisy, Jan Mares, Lubica Prochazkova, Rozsa Csilla, Jarmila Szilasiova, Pavel Stourac, Radomir Talab, Peter Turcani, Marta Vachova, Laszlo Vecsei, David Vodusek, Olga Zapletalova & Thomas Berger. (2013)
Recommendations for the Use of Prolonged‐Release Fampridine in Patients with Multiple Sclerosis (
MS
)
. CNS Neuroscience & Therapeutics 19:5, pages 302-306.
Crossref
Crossref
Andrew D. Goodman & Robert Thompson Stone. (2012) Enhancing Neural Transmission in Multiple Sclerosis (4-Aminopyridine Therapy). Neurotherapeutics 10:1, pages 106-110.
Crossref
Crossref
C. Vaney, A. Bienz, R. Zwicky, M. Gerber & M. Traber. (2012) P7. Importance of mobility for quality of life in patients with multiple sclerosis. Clinical Neurophysiology 123:10, pages e104-e105.
Crossref
Crossref
Carrie Hersh & Alex Rae-Grant. (2012) Extended-release dalfampridine in the management of multiple-sclerosis-related walking impairment. Therapeutic Advances in Neurological Disorders 5:4, pages 199-204.
Crossref
Crossref
Bernd C. KieseierCarlo Pozzilli. (2012) Assessing walking disability in multiple sclerosis. Multiple Sclerosis Journal 18:7, pages 914-924.
Crossref
Crossref